Now that we've introduced you to a variety
of the different agents
that we see in clinical practice,
how does this actually translate
into a treatment plan
for a patient?
Let's take the example of breast cancer
and look at the different modalities
and sequencing of therapy that we can utilize.
So we have traditional cytotoxic chemotherapy
that is still a big part of the treatment
of breast cancer.
We commonly will use taxanes
like paclitaxel and docetaxel,
and anthracyclines like doxorubicin.
We have a subset of breast cancers
that are estrogen
or progesterone receptor positive
and so we didn't talk too much
about hormonal therapy here
but in breast cancer and prostate cancer
and a few others,
we do use hormonal therapy a lot.
is a selective estrogen receptor modulator
and the aromatase inhibitors anastrozole,
all inhibit estrogen in different ways.
And then we also have our targeted therapy
that I started to introduce.
So again HER2 is expressed on
about 20% to 30% of breast cancers,
and we can target it
with a monoclonal antibody trastuzumab.
Pertuzumab is another monoclonal antibody
that actually works to prevent
the dimerization of HER2
with a family member that will cause
an activating pathway.
And then we also have lapatinib
which is a tyrosine kinase inhibitor
that binds on the inside of the cell
directed towards HER2 as well.